142 related articles for article (PubMed ID: 24567025)
1. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3).
Becker M; Galler A; Raile K
Pediatrics; 2014 Mar; 133(3):e775-9. PubMed ID: 24567025
[TBL] [Abstract][Full Text] [Related]
2. Treatment of young patients with HNF1A mutations (HNF1A-MODY).
Raile K; Schober E; Konrad K; Thon A; Grulich-Henn J; Meissner T; Wölfle J; Scheuing N; Holl RW;
Diabet Med; 2015 Apr; 32(4):526-30. PubMed ID: 25483937
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.
Katra B; Klupa T; Skupien J; Szopa M; Nowak N; Borowiec M; Kozek E; Malecki MT
Diabetes Technol Ther; 2010 Apr; 12(4):313-6. PubMed ID: 20210571
[TBL] [Abstract][Full Text] [Related]
4. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
5. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
[TBL] [Abstract][Full Text] [Related]
7. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.
Almutair A; Almulhem B
Front Endocrinol (Lausanne); 2024; 15():1294264. PubMed ID: 38524636
[TBL] [Abstract][Full Text] [Related]
9. MODY in Ukraine: genes, clinical phenotypes and treatment.
Globa E; Zelinska N; Elblova L; Dusatkova P; Cinek O; Lebl J; Colclough K; Ellard S; Pruhova S
J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1095-1103. PubMed ID: 28862987
[TBL] [Abstract][Full Text] [Related]
10. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection.
Ekholm E; Shaat N; Holst JJ
Acta Diabetol; 2012 Oct; 49(5):349-54. PubMed ID: 21761282
[TBL] [Abstract][Full Text] [Related]
11. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
Urbanova J; Andel M; Potockova J; Klima J; Macek J; Ptacek P; Mat'oska V; Kumstyrova T; Heneberg P
Curr Pharm Des; 2015; 21(39):5736-48. PubMed ID: 26446475
[TBL] [Abstract][Full Text] [Related]
12. Should the negativity for islet cell autoantibodies be used in a prescreening for genetic testing in maturity-onset diabetes of the young? The case of autoimmunity-associated destruction of pancreatic β-cells in a family of HNF1A-MODY subjects.
Urbanová J; Rypáčková B; Kučera P; Anděl M; Heneberg P
Int Arch Allergy Immunol; 2013; 161(3):279-84. PubMed ID: 23548576
[TBL] [Abstract][Full Text] [Related]
13. Onset of type 1 diabetes mellitus in two patients with maturity onset diabetes of the young.
Maltoni G; Zucchini S; Scipione M; Mantovani V; Salardi S; Cicognani A
Pediatr Diabetes; 2012 Mar; 13(2):208-12. PubMed ID: 21696527
[TBL] [Abstract][Full Text] [Related]
14. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
[TBL] [Abstract][Full Text] [Related]
15. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes.
Dusátková P; Průhová S; Sumník Z; Kolousková S; Obermannová B; Cinek O; Lebl J
J Pediatr Endocrinol Metab; 2011; 24(5-6):377-9. PubMed ID: 21823540
[TBL] [Abstract][Full Text] [Related]
16. Maturity onset diabetes of the young: Seek and you will find.
Heuvel-Borsboom H; de Valk HW; Losekoot M; Westerink J
Neth J Med; 2016 Jun; 74(5):193-200. PubMed ID: 27323672
[TBL] [Abstract][Full Text] [Related]
17. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
[TBL] [Abstract][Full Text] [Related]
18. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?
Karlsson E; Shaat N; Groop L
Diabet Med; 2008 Jul; 25(7):788-91. PubMed ID: 18513302
[TBL] [Abstract][Full Text] [Related]
19. Three novel mutations in MODY and its phenotype in three different Czech families.
Bazalová Z; Rypácková B; Broz J; Brunerová L; Polák J; Rusavý Z; Treslová L; Andel M
Diabetes Res Clin Pract; 2010 May; 88(2):132-8. PubMed ID: 20132997
[TBL] [Abstract][Full Text] [Related]
20. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
